Lacosamide as monotherapy in focal seizure: Literature review

Kishore R. Sonkusare; Hanmant V. Barkate

doi:10.1016/j.ijep.2016.12.006

International Journal of Epilepsy, Inhaltsverzeichnis

CC-BY-NC-ND 4.0 · International Journal of Epilepsy 2017; 04(01): 055-058
DOI: 10.1016/j.ijep.2016.12.006

Review article

Thieme Medical and Scientific Publishers Private Ltd.

Lacosamide as monotherapy in focal seizure: Literature review

Authors

Kishore R. Sonkusare

¹Department of Medical Affairs, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India
Hanmant V. Barkate

¹Department of Medical Affairs, Intas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India

Abstract

Lacosamide is a newer approved antiepileptic drug (AED) characterized by its novel pharmacodynamic profile. It is now approved by United States Food and Drug Administration for use as monotherapy in adults (aged>17 years) with focal seizures based on historical controlled trial by Wechsler RT et al in 2014. Randomized controlled trials on lacosamide monotherapy have demonstrated significant reduction in median seizure frequency. In addition, 50% responder rates for lacosamide was noted in half of the patients, with retention rate in two third of patients in 1 year follow up period. Adverse events reported in clinical trials were mostly mild to moderate in intensity. The most common adverse events were dizziness, headache, convulsion, nausea and fatigue while convulsion and dizziness were commonly responsible for drug discontinuation. Overall, lacosamide monotherapy can be a good treatment option in patients with focal seizure.

Key words

Lacosamide - Monotherapy - Historical controlled trial - Focal seizure

Volltext

Referenzen

References
1 Fisher RS, Acevedo C, Arzimanoglou A. et al. ILAE official report: a practical clinical definition of epilepsy. Epilepsia 55 April (4) 2014; 475-482
2 Berg AT, Berkovic SF, Brodie MJ. et al. Revised terminology and concepts for organization of seizures and epilepsies: report of the ILAE commission on classification and terminology, 2005–2009. Epilepsia 51 April (4) 2010; 676-685
3 de Boer HM, Mula M, Sander JW. The global burden and stigma of epilepsy. Epilepsy Behav 12 May (4) 2008; 540-546
4 Bharucha NE. Epidemiology of epilepsy in India. Epilepsia 44 s1 2003; 9-11
5 Shneker BF, Fountain NB. Epilepsy Dis Mon. 49 July (7) 2003; 426-478
6 Felbatol. (felbamate) US prescribing information. Somerset, NJ: MEDA Pharmaceuticals Inc.; 2012 [Internet]. [cited 2016 Mar 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020189s022lbl.pdf
7 Lamictal. (lamotrigine) Summary of product characteristics. Uxbridge, Middlesex, UK: GlaxoSmithKline UK; 2013 [Internet]. [cited 2016 Mar 21]. Available from: http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/PediatricAdvisoryCommittee/UCM235547.pdf
8 Trileptal. (oxcarbazepine) Summary of product characteristics. Camberley, Surrey, UK: Novartis Pharmaceuticals UK Ltd; 2013 [Internet]. [cited 2016 Mar 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/021014s026,021285s021lbl.pdf
9 Topamax. (topiramate) US prescribing information. Titusville, NJ: Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc.; 2013 [Internet]. [cited 2016 Mar 21]. Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2009/020505s038s039,020844s032s034lbl.pdf
10 French JA, Temkin NR, Shneker BF. et al. Conversion to monotherapy: first study using a historical control group. Neurotherapeutics 9 January (1) 2012; 176-184
11 Chung S, Ceja H, Gawłowicz J. et al. Levetiracetam extended release conversion to monotherapy for the treatment of patients with partial-onset seizures: a double-blind, randomised, multicentre, historical control study. Epilepsy Res 101 August (1–2) 2012; 92-102
12 French J, Kwan P, Fakhoury T. et al. Pregabalin monotherapy in patients with partial-onset seizures: a historical-controlled trial. Neurology 82 February (7) 2014; 590-597
13 Sperling MR, Harvey J, Grinnell T, Cheng H, Blum D. the 045 Study Team Efficacy and safety of conversion to monotherapy with eslicarbazepine acetate in adults with uncontrolled partial-onset seizures: a randomized historical-control phase III study based in North America. Epilepsia 56 April (4) 2015; 546-555
14 Beyreuther BK, Freitag J, Heers C, Krebsfänger N, Scharfenecker U, Stöhr T. Lacosamide a review of preclinical properties. CNS Drug Rev 13 (01) 2007; 21-42
15 European Medicines Agency. Lacosamide: summary of product characteristics. [Internet]. [cited 2016 Mar 22]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000863/WC500050338.pdf
16 US FDA. Vimpat (lacosamide): highlights of prescribing information. [Internet]. [cited 2016 Mar 22]. Available from: http://www.vimpat.com/PDF/vimpat_PI.pdf
17 Curia G, Biagini G, Perucca E, Avoli M. Lacosamide. CNS Drugs 23 (07) 2009; 555-568
18 Doty P, Rudd GD, Stoehr T, Thomas D. Lacosamide. Neurotherapeutics 4 (01) 2007; 145-148
19 de Biase S, Gigli GL, Valente M, Merlino G. Lacosamide for the treatment of epilepsy. Expert Opin Drug Metab Toxicol 10 March (3) 2014; 459-468
20 Kellinghaus C. Lacosamide as treatment for partial epilepsy: mechanisms of action, pharmacology, effects, and safety. Ther Clin Risk Manag 5 2009; 757-766
21 Wolff C, Carrington B, Varrin-Doyer M. et al. Drug binding assays do not reveal specific binding of lacosamide to collapsin response mediator protein 2 (CRMP-2): no specific binding of lacosamide to CRMP-2. CNS Neurosci Ther 18 June (6) 2012; 493-500
22 Scott LJ. Lacosamide a review in focal seizures in patients with epilepsy. Drugs 75 December (18) 2015; 2143-2154
23 Beydoun A, D’souza J, Hebert D, Lacosamide DotyP. pharmacology, mechanisms of action and pooled efficacy and safety data in partial-onset seizures. Expert Rev Neurother 9 January (1) 2009; 33-42
24 Wechsler RT, Li G, French J. et al. Conversion to lacosamide monotherapy in the treatment of focal epilepsy: Results from a historical-controlled, multicenter, double-blind study. Epilepsia. 55 July (7) 2014; 1088-1098
25 Lattanzi S, Cagnetti C, Foschi N, Provinciali L, Silvestrini M. Lacosamide monotherapy for partial onset seizures. Seizure 27 April 2015; 71-74
26 Giráldez BG, Toledano R, García-Morales I. et al. Long-term efficacy and safety of lacosamide monotherapy in the treatment of partial-onset seizures: a multicenter evaluation. Seizure 29 July 2015; 119-122
27 Ryvlin P, Sperling M, Chung S. et al. Conversion to lacosamide monotherapy: post hoc analysis on responder and seizure freedom rates [abstract no 3.292]. 68th Annual Meeting of the American Epilepsy Society. 2014 [Internet]. [cited 2016 Mar 25]. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868740
28 Stern J, Sperling M, Chung S. et al. Focal seizure frequency by study phase and seizure type in conversion to lacosamide monotherapy study: a post hoc analysis [abstract no 3.291]. 68th Annual Meeting of the American Epilepsy Society. 2014 [Internet]. [cited 2016 Mar 23]. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868739
29 Durgin T, Wade R, Chen CC. et al. Lacosamide monotherapy treatment pathways in epilepsy patients in a US managed care population [abstract no 2.297]. 68th Annual Meeting of the American Epilepsy Society. 2014 [Internet]. [cited 2016 Mar 25]. Available from: https://www.aesnet.org/meetings_events/annual_meeting_abstracts/view/1868379